Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Hauser, SL; Bar-Or, A; Comi, G; Giovannoni, G; Hartung, H-P; Hemmer, B; Lublin, F; Montalban, X; Rammohan, KW; Selmaj, K; Traboulsee, A; Wolinsky, JS; Arnold, DL; Klingelschmitt, G; Masterman, D; Fontoura, P; Belachew, S; Chin, P; Mairon, N; Garren, H; Kappos, L; Clinical, OPERAIOPERAII

View/Open

Published version (285.3Kb)

Volume

376

Pagination

221 - 234

DOI

10.1056/NEJMoa1601277

Journal

NEW ENGLAND JOURNAL OF MEDICINE

Issue

ISSN

0028-4793

Metadata

Show full item record

Authors

Hauser, SL; Bar-Or, A; Comi, G; Giovannoni, G; Hartung, H-P; Hemmer, B; Lublin, F; Montalban, X; Rammohan, KW; Selmaj, K

URI

http://qmro.qmul.ac.uk/xmlui/handle/123456789/18940

Collections

Centre for Neuroscience, Surgery and Trauma [1118]

Licence information

From New England Journal of Medicine, Hauser, S.L. et al., Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, 376:221-234. DOI: 10.1056/NEJMoa1601277. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission.